You don't have permission to access "http://www.medpagetoday.com/quizzes/news-quiz/120297" on this server. Reference #18.61f4d517.1773558213.8145d53 https://errors.edgesuite.net/18.61f4d517.1773558213.8145d53
TOPLINE: Among patients with obesity and type 2 diabetes (T2D), those who underwent metabolic bariatric surgery experienced greater weight loss and reductions in A1c levels than patients who did not undergo surgery. METHODOLOGY: Researchers conducted a retrospective cohort study using data of 411 adults with T2D and obesity (mean age, 48.3 years; 63.3% women; mean
Please complete security verification This request seems a bit unusual, so we need to confirm that you're human. Please press and hold the button until it turns completely green. Thank you for your cooperation! Press and hold the button If you believe this is an error, please contact our support team. 185.149.70.50 : 5669a5b8-344c-43a3-b2b8-3d6b28a4
"Before the appendectomy, I was looking for property and homes to purchase, and that is pretty much completely off the table right now," says Shannon Harness, a veteran who was uninsured when he had two appendicitis-related surgeries in 2019. The bills amounted to $80,232. Rachel Woolf/Rachel Woolf for KHN hide caption toggle caption Rachel Woolf/Rachel…
Published: October 30, 2026, 10:16 pm Several reports of children choking have led to an FDA warning against Once Upon A Time snacks. The warning covers all flavors, quantities, lots and dates of Once Upon A Farm Tractor Wheels Organic, Toddler Soft-Baked Bars. The FDA has received several reports that describe infants ages 1.5 to
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.